Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial (vol 8, pg 582, 2020)

被引：0

作者：

Cherney, D. Z. I.

Dekkers, C. C. J.

Barbour, S. J.

机构：

来源：

LANCET DIABETES & ENDOCRINOLOGY | 2020年 / 8卷 / 08期

关键词：

D O I：

10.1016/S2213-8587(20)30217-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E3 / E3

页数：1

共 50 条

[41] Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination with Loop Diuretics in Patients with Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial (vol 142, pg 1713, 2020)
Mordi, N. A.
CIRCULATION, 2020, 142 (18) : E316 - E316
[42] Anti-inflammatory response to Cymbopogon citratus (DC.) Stapf extract in non-diabetic chronic kidney disease stage 3: A randomized, double-blind, placebo-controlled clinical trial
Wongmanit, Patnaree
Sriyakul, Kusuma
Tungsukruthai, Parunkul
Supasyndh, Ouppatham
Tungsukruthai, Sucharat
Phetkate, Pratya
JOURNAL OF PHARMACY & PHARMACOGNOSY RESEARCH, 2025, 13 (03): : 892 - 904
[43] Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial (vol 7, pg 606, 2019)
Mosenzon, O.
Wiviott, S. D.
Cahn, A.
LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (08): : E20 - E20
[44] Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial
Agarwal, Rajiv
Rossignol, Patrick
Romero, Alain
Garza, Dahlia
Mayo, Martha R.
Warren, Suzette
Ma, Jia
White, William B.
Williams, Bryan
LANCET, 2019, 394 (10208): : 1540 - 1550
[45] The effects of selenium supplementation on biomarkers of inflammation and oxidative stress in patients with diabetic nephropathy: a randomised, double-blind, placebo-controlled trial (Expression of Concern of Vol 116, Pg 1222, 2016)
Bahmani, Fereshteh
Kia, Mahsa
Soleimani, Alireza
Mohammadi, Ali Akbar
Asemi, Zatollah
BRITISH JOURNAL OF NUTRITION, 2022, 127 (01) : 155 - 155
[46] Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials (vol 8, pg 169, 2014)
Maltais, F.
Singh, S.
Donald, A.
Crater, G.
Church, A.
Goh, A.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2016, 10 (03) : 289 - 289
[47] Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo controlled trial (vol 5, pg 877, 2017)
Holman, R. R.
Coleman, R. L.
Chan, J. C. N.
LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (11): : E7 - E7
[48] Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial (vol 395, pg 1126, 2020)
Mease, P. J.
Rahman, P.
Gottlieb, A. B.
LANCET, 2020, 395 (10230): : 1114 - 1114
[49] Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial (vol 4, pg 1004, 2016)
Frias, J. P.
Guja, C.
Hardy, E.
LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (12): : E8 - E8
[50] Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial (vol 2, pg 187, 2014)
Zheng, J-P
Wen, F-Q
Bai, C-X
LANCET RESPIRATORY MEDICINE, 2014, 2 (04): : E4 - E4

← 1 2 3 4 5 →